CHICAGOâ€”Drugs designed to unleash the body's own immune system against cancer are significantly prolonging the lives of some people with hard-to-treat forms of the deadly disease.. The latest evidence: Patients with the skin cancer melanoma who received a combination of two Bristol-Myers Squibb Co. immunotherapies in a clinical trial lived an average of more than three years, researchers reported Monday. In another study, about 70% of advanced melanoma patients receiving a Merck & Co. immunotherapy were still alive after...
  